Literature DB >> 485833

Predicting success of forefoot amputations in diabetics by noninvasive testing.

G W Gibbons, F C Wheelock, C S Hoar, J L Rowbotham, C Siembieda.   

Abstract

Sixty-six diabetic patients underwent needed forefoot amputations when clinical assessment indicated a reasonable chance of healing. All patients underwent noninvasive testing consisting of segmental systolic pressure measurements and pulse volume recordings (PVRs) taken at the thigh, calf, ankle, and forefoot levels. Segmental systolic pressures were falsely high (greater than 200 mm Hg) and therefore not useful in 56%. Ankle systolic pressures predicted failure in 36% of patients who healed and success in 64% who failed to heal. Segmental PVRs were sequentially predictive in only 50%. Forefoot PVR traces predicted failure in 50% of patients whose amputations healed. No patient should be denied a forefoot amputation solely on the basis of unfavorable results of noninvasive tests. Favorable clinical signs and a strongly positive forefoot PVR trace are the best predictors of successful forefoot amputations in diabetic patients.

Entities:  

Mesh:

Year:  1979        PMID: 485833     DOI: 10.1001/archsurg.1979.01370330056010

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  3 in total

1.  Pupil motility in long-term diabetes.

Authors:  R C Bryant
Journal:  Diabetologia       Date:  1980       Impact factor: 10.122

2.  Definitive surgical treatment of infected or exposed ventral hernia mesh.

Authors:  Steven R Szczerba; Gregory A Dumanian
Journal:  Ann Surg       Date:  2003-03       Impact factor: 12.969

3.  Long-term prognosis of diabetic patients with critical limb ischemia: a population-based cohort study.

Authors:  Ezio Faglia; Giacomo Clerici; Jacques Clerissi; Livio Gabrielli; Sergio Losa; Manuela Mantero; Maurizio Caminiti; Vincenzo Curci; Antonella Quarantiello; Tommaso Lupattelli; Tommaso Luppattelli; Alberto Morabito
Journal:  Diabetes Care       Date:  2009-02-17       Impact factor: 17.152

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.